


## How is MyaReg structured?

MyaReg is managed by a user council elected from the medical advisory board of DMG to coordinate requests for data use. MyaReg thus enables patient-oriented research into the care, diagnosis, therapy, and course of myasthenic diseases.


Together with the central Mya-Biobank (hosted by the University Hospital Munster, Germany), MyaReg will facilitate biomarker research on the pathophysiology, diagnostics, and prognosis of myasthenia gravis to identify modifiable impact factors on the natural disease course and outcome parameters.



## About MyaReg

The German Myasthenia Registry, or **MyaReg** for short, is assessing and evaluating clinical routine data from patients suffering from myasthenic syndromes, including myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS). The primary goal of MyaReg is to improve the quality of patient care. Besides assessing clinical routine data, the register will also collect patient-reported outcome measures.

MyaReg was initiated and established by the medical advisory board in cooperation with the German Masthenia Foundation (DMG e. V.), supported by the German Institute for Quality and Patient Safety (BQS). MyaReg is based on a defined set of quality indicators and uses a web-based database (ASTHESIS®).



Herausgeber:

**Deutsche Myasthenie Gesellschaft e. V.**

Adresse: Westerstraße 93  
28199 Bremen

Telefon: 0421 592060

E-Mail: [info@dmg.online](mailto:info@dmg.online)

Internet: [www.dmg.online](http://www.dmg.online)




**Deutsches  
Myasthenie  
Register**

**MyaReg**  
German Myasthenia Registry

## What data do we collect?

German Myasthenia Registry	
Patients with myasthenic syndromes including LEMS and CMS	
Longitudinal design	



## Where does the data come from?

All certified integrated Myasthenia Centres (iMZ) in Germany, providing care for more than 3500 MG patients, participate in the registry. The certification process is based on the full participation in the registry based on the yearly published quality report. Every patient with a myasthenic syndrome treated in an iMZ will be asked to provide informed consent for participation in the registry.

